Jointcare Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
as on 24-10-2024
- Revenue 45.73%
(FY 2023)
- Profit 21.15%
(FY 2023)
- Ebitda 55.70%
(FY 2023)
- Net Worth 22.43%
(FY 2023)
- Total Assets 77.67%
(FY 2023)
About Jointcare Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 Cr.
Poornima Saini and Vipin Saini serve as directors at the Company.
- CIN/LLPIN
U24100HR2011PTC042949
- Company No.
042949
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Faridabad, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Jointcare Pharmaceuticals Private Limited offer?
Jointcare Pharmaceuticals Private Limited offers a wide range of products and services, including Vitamins & Supplements, Mineral Supplements.
Who are the key members and board of directors at Jointcare Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Poornima Saini  | Director | 16-May-2011 | Current |
| Vipin Saini | Director | 12-Sep-2011 | Current |
Financial Performance of Jointcare Pharmaceuticals.
Jointcare Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 45.73% increase. The company also saw a substantial improvement in profitability, with a 21.15% increase in profit. The company's net worth Soared by an impressive increase of 22.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jointcare Pharmaceuticals?
In 2022, Jointcare Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Thumsvit Healthcare Private LimitedActive 3 years 4 monthsPoornima Saini and Vipin Saini are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Jul 2023 | ₹1.00 Cr | Open |
Yes Bank Limited Creation Date: 07 Apr 2022 | ₹1.00 Cr | Open |
How Many Employees Work at Jointcare Pharmaceuticals?
Jointcare Pharmaceuticals has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jointcare Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jointcare Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
